FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514938762> ?p ?o ?g. }

• W2514938762 endingPage "68841" @default.
• W2514938762 startingPage "68833" @default.
• W2514938762 abstract "// Shruti Sharma 1, * , Natalie Galanina 2, * , Ailin Guo 1, * , Jimmy Lee 1 , Sabah Kadri 1, 3 , Charles Van Slambrouck 1 , Bradley Long 1 , Weige Wang 1 , Mei Ming 1 , Larissa V. Furtado 1 , Jeremy P. Segal 1 , Wendy Stock 2 , Girish Venkataraman 1 , Wei-Jen Tang 4 , Pin Lu 1 , Yue Lynn Wang 1 1 Department of Pathology, University of Chicago, Chicago, IL 60637, USA 2 Department of Medicine, University of Chicago, Chicago, IL 60637, USA 3 Center for Research Informatics, University of Chicago, Chicago, IL 60637, USA 4 Ben-May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA * These authors have contributed equally to this work Correspondence to: Yue Lynn Wang, email: ylwang@bsd.uchicago.edu Keywords: chronic lymphocytic leukemia, Richter transformation, ibrutinib resistance, BTK , molecular targeted therapy Received: June 04, 2016     Accepted: August 15, 2016     Published: September 10, 2016 ABSTRACT Ibrutinib (ibr), a first-in-class Bruton tyrosine kinase (BTK) inhibitor, has demonstrated high response rates in both relapsed/refractory and treatment naive chronic lymphocytic leukemia (CLL). However, about 25% of patients discontinue ibrutinib therapy at a median follow-up of 20 months and many patients discontinue the treatment due to leukemia progression or Richter transformation. Mutations affecting the C481 residue of BTK disrupt ibrutinib binding and have been characterized by us and others as the most common mechanism of ibrutinib resistance. Thus far, all described BTK mutations are located in its kinase domain and mutations outside this domain have never been described. Herein, we report a patient whose CLL progressed, was salvaged with ibrutinib and then relapsed. Serial analysis of samples throughout patient’s clinical course identified a structurally novel mutation ( BTK T316A ) in the SH2 domain, but not kinase domain, of Bruton tyrosine kinase which was associated with disease relapse. Functionally, cells carrying BTK T316A show resistance to ibrutinib at both cellular and molecular levels to a similar extent as BTK C481S . Our study lends further insight into the diverse mechanisms of ibrutinib resistance that has important implications for the development of next-generation BTK inhibitors as well as mutation detection in relapsed patients." @default.
• W2514938762 created "2016-09-16" @default.
• W2514938762 creator A5005401772 @default.
• W2514938762 creator A5005939966 @default.
• W2514938762 creator A5019530686 @default.
• W2514938762 creator A5019988717 @default.
• W2514938762 creator A5024110359 @default.
• W2514938762 creator A5042629306 @default.
• W2514938762 creator A5046480613 @default.
• W2514938762 creator A5049498138 @default.
• W2514938762 creator A5051184287 @default.
• W2514938762 creator A5056977572 @default.
• W2514938762 creator A5062327095 @default.
• W2514938762 creator A5062344658 @default.
• W2514938762 creator A5069007468 @default.
• W2514938762 creator A5085031013 @default.
• W2514938762 creator A5091437985 @default.
• W2514938762 date "2016-09-10" @default.
• W2514938762 modified "2023-10-18" @default.
• W2514938762 title "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL" @default.
• W2514938762 cites W1606823171 @default.
• W2514938762 cites W1979816280 @default.
• W2514938762 cites W1979834961 @default.
• W2514938762 cites W1999128869 @default.
• W2514938762 cites W2001343785 @default.
• W2514938762 cites W2024216962 @default.
• W2514938762 cites W2027648780 @default.
• W2514938762 cites W2042132765 @default.
• W2514938762 cites W2044421331 @default.
• W2514938762 cites W2046543570 @default.
• W2514938762 cites W2047415399 @default.
• W2514938762 cites W2067064694 @default.
• W2514938762 cites W2071549499 @default.
• W2514938762 cites W2080588958 @default.
• W2514938762 cites W2108234281 @default.
• W2514938762 cites W2151770757 @default.
• W2514938762 cites W2166693967 @default.
• W2514938762 cites W2168013497 @default.
• W2514938762 cites W2171594021 @default.
• W2514938762 cites W2181172392 @default.
• W2514938762 cites W2211564719 @default.
• W2514938762 cites W2233614027 @default.
• W2514938762 cites W2267257595 @default.
• W2514938762 cites W4247053599 @default.
• W2514938762 doi "https://doi.org/10.18632/oncotarget.11932" @default.
• W2514938762 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5356593" @default.
• W2514938762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27626698" @default.
• W2514938762 hasPublicationYear "2016" @default.
• W2514938762 type Work @default.
• W2514938762 sameAs 2514938762 @default.
• W2514938762 citedByCount "63" @default.
• W2514938762 countsByYear W25149387622016 @default.
• W2514938762 countsByYear W25149387622017 @default.
• W2514938762 countsByYear W25149387622018 @default.
• W2514938762 countsByYear W25149387622019 @default.
• W2514938762 countsByYear W25149387622020 @default.
• W2514938762 countsByYear W25149387622021 @default.
• W2514938762 countsByYear W25149387622022 @default.
• W2514938762 countsByYear W25149387622023 @default.
• W2514938762 crossrefType "journal-article" @default.
• W2514938762 hasAuthorship W2514938762A5005401772 @default.
• W2514938762 hasAuthorship W2514938762A5005939966 @default.
• W2514938762 hasAuthorship W2514938762A5019530686 @default.
• W2514938762 hasAuthorship W2514938762A5019988717 @default.
• W2514938762 hasAuthorship W2514938762A5024110359 @default.
• W2514938762 hasAuthorship W2514938762A5042629306 @default.
• W2514938762 hasAuthorship W2514938762A5046480613 @default.
• W2514938762 hasAuthorship W2514938762A5049498138 @default.
• W2514938762 hasAuthorship W2514938762A5051184287 @default.
• W2514938762 hasAuthorship W2514938762A5056977572 @default.
• W2514938762 hasAuthorship W2514938762A5062327095 @default.
• W2514938762 hasAuthorship W2514938762A5062344658 @default.
• W2514938762 hasAuthorship W2514938762A5069007468 @default.
• W2514938762 hasAuthorship W2514938762A5085031013 @default.
• W2514938762 hasAuthorship W2514938762A5091437985 @default.
• W2514938762 hasBestOaLocation W25149387621 @default.
• W2514938762 hasConcept C104317684 @default.
• W2514938762 hasConcept C116834253 @default.
• W2514938762 hasConcept C126322002 @default.
• W2514938762 hasConcept C170493617 @default.
• W2514938762 hasConcept C203014093 @default.
• W2514938762 hasConcept C2777938653 @default.
• W2514938762 hasConcept C2778461978 @default.
• W2514938762 hasConcept C2779878957 @default.
• W2514938762 hasConcept C42362537 @default.
• W2514938762 hasConcept C501734568 @default.
• W2514938762 hasConcept C502942594 @default.
• W2514938762 hasConcept C54355233 @default.
• W2514938762 hasConcept C59822182 @default.
• W2514938762 hasConcept C71924100 @default.
• W2514938762 hasConcept C86803240 @default.
• W2514938762 hasConcept C90059517 @default.
• W2514938762 hasConcept C98274493 @default.
• W2514938762 hasConceptScore W2514938762C104317684 @default.
• W2514938762 hasConceptScore W2514938762C116834253 @default.
• W2514938762 hasConceptScore W2514938762C126322002 @default.
• W2514938762 hasConceptScore W2514938762C170493617 @default.
• W2514938762 hasConceptScore W2514938762C203014093 @default.

• next